TRK Inhibition Continues to Advance the Lung Cancer Field
Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
Luis E. Raez, MD, the medical director and chief scientific officer at Memorial Cancer Institute, Memorial Health Care System, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
NTRK fusions are a relatively new target in the lung cancer space, says Raez. Despite their novelty, NTRK fusions are important because they are changing the face of cancer treatment. The reach of NTRK fusions spans 18 different adult and pediatric cancers, he explains.
The original data around the TRK inhibitor, larotrectinib (Vitrakvi) showed that patients will respond to TRK inhibition. This research was revolutionary for lung cancers and other solid tumors because it further solidified the role of genetic testing and targeted therapy for these patient groups.
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
September 13th 2024The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.
Read More
Consolidation Durvalumab Shows Consistent Survival Improvements in LS-SCLC Subgroups
September 13th 2024The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.
Read More
